CA2417686A1 - Manufacture of oral dosage forms delivering both immediate release and sustained release drugs - Google Patents

Manufacture of oral dosage forms delivering both immediate release and sustained release drugs Download PDF

Info

Publication number
CA2417686A1
CA2417686A1 CA002417686A CA2417686A CA2417686A1 CA 2417686 A1 CA2417686 A1 CA 2417686A1 CA 002417686 A CA002417686 A CA 002417686A CA 2417686 A CA2417686 A CA 2417686A CA 2417686 A1 CA2417686 A1 CA 2417686A1
Authority
CA
Canada
Prior art keywords
release
drug
immediate
prolonged
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002417686A
Other languages
French (fr)
Other versions
CA2417686C (en
Inventor
Jong Lim
John N. Shell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assertio Therapeutics Inc
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depomed Inc filed Critical Depomed Inc
Publication of CA2417686A1 publication Critical patent/CA2417686A1/en
Application granted granted Critical
Publication of CA2417686C publication Critical patent/CA2417686C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A method is disclosed for manufacturing a pharmaceutical tablet for oral administration, the tablet combining both immediate-release and prolonged-release modes of drug delivery and using an immediate-release drug that is either insoluble in water or only sparingly soluble and is present in a very small amount compared to the prolonged-release drug. The method involves the use of particles of the immediate-release drug that are equal to or less than 10 microns in diameter, applied as a layer or coating over a core of the prolonged-release drug, the layer or coating being either the drug particles themselves, applied as an aqueous suspension, or a solid mixture containing the drug in admixture with a material that disintegrates rapidly in gastric fluid. The result in both cases is a high degree of uniformity in the proportions of the immediate-release and prolonged-release drugs, uniformity that is otherwise difficult to achieve in view of the insolubility of the immediate-release drug and its relatively small amount compared to the prolonged-released drug.
CA002417686A 2002-02-01 2003-01-30 Manufacture of oral dosage forms delivering both immediate release and sustained release drugs Expired - Fee Related CA2417686C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/066,146 2002-02-01
US10/066,146 US6682759B2 (en) 2002-02-01 2002-02-01 Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs

Publications (2)

Publication Number Publication Date
CA2417686A1 true CA2417686A1 (en) 2003-08-01
CA2417686C CA2417686C (en) 2006-06-06

Family

ID=27658647

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002417686A Expired - Fee Related CA2417686C (en) 2002-02-01 2003-01-30 Manufacture of oral dosage forms delivering both immediate release and sustained release drugs

Country Status (11)

Country Link
US (1) US6682759B2 (en)
EP (1) EP1469838A4 (en)
JP (1) JP2005521674A (en)
KR (1) KR100680574B1 (en)
AU (1) AU2003207755B2 (en)
CA (1) CA2417686C (en)
IL (1) IL163205A (en)
MX (1) MXPA04007371A (en)
NZ (1) NZ534312A (en)
TW (1) TWI280141B (en)
WO (1) WO2003066028A1 (en)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
DE60219963T2 (en) * 2002-01-25 2008-02-07 Laboratorios Silanes, S.A. De C.V. PHARMACEUTICAL COMPOSITION USED FOR GLUCOSE CONTROL IN THE BLOOD OF PATIENTS WITH DIABETES TYPE 2
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
ES2208123A1 (en) * 2002-11-29 2004-06-01 Laboratorios Del Dr. Esteve, S.A. Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function
US20040147509A1 (en) 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
RU2350327C2 (en) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Compounds causing weight loss
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8313776B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
ATE454138T1 (en) * 2003-08-08 2010-01-15 Biovail Lab Int Srl MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE
EP1653925A1 (en) * 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
JP5686494B2 (en) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド Antibiotic preparations, their use and preparation
JP2007513869A (en) * 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
JP4361461B2 (en) * 2003-10-31 2009-11-11 武田薬品工業株式会社 Solid preparation
WO2005041962A1 (en) * 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
DE602004030931D1 (en) * 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
EP1691786A1 (en) * 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
DK1691787T3 (en) * 2003-12-04 2008-09-22 Pfizer Prod Inc Method of Forming Small Particles
CN1889933A (en) * 2003-12-04 2007-01-03 辉瑞产品公司 Azithromycin multiparticulate dosage forms by liquid-based processes
EP1689368B1 (en) * 2003-12-04 2016-09-28 Bend Research, Inc Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
KR20080064209A (en) * 2003-12-04 2008-07-08 화이자 프로덕츠 인코포레이티드 Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
US20050142187A1 (en) * 2003-12-24 2005-06-30 Treacy Donald J.Jr. Enhanced absorption of modified release dosage forms
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005102290A1 (en) * 2004-04-22 2005-11-03 Ranbaxy Laboratories Limited Pharmaceutical compositions of a biguanide and a sulfonylurea
SE0401031D0 (en) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US7588779B2 (en) * 2004-05-28 2009-09-15 Andrx Labs, Llc Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
US20060002986A1 (en) * 2004-06-09 2006-01-05 Smithkline Beecham Corporation Pharmaceutical product
US20060002594A1 (en) * 2004-06-09 2006-01-05 Clarke Allan J Method for producing a pharmaceutical product
US8101244B2 (en) * 2004-06-09 2012-01-24 Smithkline Beecham Corporation Apparatus and method for producing or processing a product or sample
TWI356036B (en) * 2004-06-09 2012-01-11 Smithkline Beecham Corp Apparatus and method for pharmaceutical production
DE102004030880A1 (en) * 2004-06-25 2006-01-12 Merck Patent Gmbh Method for the treatment of diabetes
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
CN1988889A (en) * 2004-07-22 2007-06-27 株式会社太平洋 Sustained-release preparations containing topiramate and the producing method thereof
US20060029641A1 (en) * 2004-08-05 2006-02-09 Keller Nathan I Calcium and magnesium nutritional supplement
CN100459982C (en) * 2004-08-30 2009-02-11 鲁南制药集团股份有限公司 Dispersible tablet of doxifluridine
KR100760430B1 (en) 2004-12-31 2007-10-04 한미약품 주식회사 Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof
JP4856881B2 (en) * 2005-02-01 2012-01-18 川澄化学工業株式会社 Drug sustained release system
EP1928421A2 (en) * 2005-06-10 2008-06-11 Combino Pharm, S.L. Formulations containing glimepiride and/or its salts
PL1919466T3 (en) 2005-07-11 2012-05-31 Cortria Corp Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative
DE102005034484A1 (en) * 2005-07-20 2007-02-01 Alfred E. Tiefenbacher Gmbh & Co.Kg Process for the preparation of glimepiride-containing pharmaceutical compositions
JP2007031377A (en) * 2005-07-28 2007-02-08 Nichi-Iko Pharmaceutical Co Ltd Glimepiride-containing drug excellent in usability
KR100780553B1 (en) * 2005-08-18 2007-11-29 한올제약주식회사 Pharmaceutical compositions and formulations of Metformin extended release tablets and its preparing method
MXPA05009633A (en) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Stable pharmaceutical composition comprising immediate-release glimepiride and delayed-release metformin.
ATE555657T1 (en) * 2005-09-29 2012-05-15 Syngenta Participations Ag FUNGICIDE COMPOSITIONS
BRPI0618918B8 (en) * 2005-11-22 2021-05-25 Nalpropion Pharmaceuticals Llc use of a first compound and a second compound to treat a blood glucose condition
WO2007062228A1 (en) * 2005-11-28 2007-05-31 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
ES2576258T3 (en) 2005-12-22 2016-07-06 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CA2635594A1 (en) * 2005-12-30 2007-07-12 Advancis Pharmaceutical Corporation Gastric release pulse system for drug delivery
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
KR100858848B1 (en) * 2006-05-23 2008-09-17 한올제약주식회사 Pharmaceutical compositions and formulations of Metformin extended release tablets
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008010690A1 (en) * 2006-07-21 2008-01-24 Handok Pharmaceuticals Co., Ltd. Gastric retention-type pellet and the preparation method thereof
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
KR100812538B1 (en) * 2006-10-23 2008-03-11 한올제약주식회사 Controlled release complex formulation comprising metformin and glimepiride
KR100985254B1 (en) * 2006-10-30 2010-10-04 한올바이오파마주식회사 Controlled release complex composition comprising angiotensin???receptor blockers and HMG-CoA reductase inhibitors
RU2009116834A (en) * 2006-11-09 2010-12-20 Ориксиджен Терапьютикс, Инкорпорэйтд Сша/Сша (Us) METHOD FOR ADMINISTRATION OF MEDICINES FOR REDUCING WEIGHT
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
MX2009001711A (en) 2006-11-17 2009-05-08 Supernus Pharmaceuticals Inc Sustained-release formulations of topiramate.
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
MX2010001071A (en) * 2007-07-27 2010-03-09 Depomed Inc Pulsatile gastric retentive dosage forms.
WO2009017383A2 (en) * 2007-08-02 2009-02-05 Handok Pharmaceuticals Co., Ltd. Sustained-release formulation comprising metformin acid salt
WO2009021127A2 (en) * 2007-08-07 2009-02-12 Neurogen Corporation Controlled released compositions
US8356315B2 (en) * 2007-12-03 2013-01-15 Koncelik Jr Lawrence J Setting television default channel
EP2255796A2 (en) * 2008-02-22 2010-12-01 HanAll Biopharma Co., Ltd. Pharmaceutical preparation
KR20090091075A (en) * 2008-02-22 2009-08-26 한올제약주식회사 Pharmaceutical preparation for treating cardiovascular disease
KR100949273B1 (en) * 2008-02-22 2010-03-25 한올제약주식회사 Combined Formulation
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en) * 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
KR20090114325A (en) * 2008-04-29 2009-11-03 한올제약주식회사 Pharmaceutical formulation
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Methods for treating visceral fat conditions
BRPI0917206B1 (en) 2008-07-31 2018-04-17 Clarke Mosquito Control Products, Inc. METHOD FOR THE FORMATION OF A DOUBLE RELEASED TABLET, TABLETS AND METHOD FOR THE MANUFACTURE OF AN EXTENDED SOLID MATRIX
WO2010019915A1 (en) * 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
EP3045043B1 (en) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
EP2403487A2 (en) 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
EP3195896A1 (en) 2009-05-05 2017-07-26 Board of Regents, The University of Texas System Novel formulations of volatile anesthetics and methods of use for reducing inflammation
AU2010286354A1 (en) * 2009-08-31 2012-04-19 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
TWI491395B (en) 2009-09-30 2015-07-11 Ct Lab Inc Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders
EP2486918A4 (en) * 2009-10-09 2014-02-26 Yungjin Pharmaceutical Co Ltd Pharmaceutical composition with both immediate and extended release characteristics
MX2012005365A (en) 2009-11-13 2012-05-29 Bristol Myers Squibb Co Immediate release tablet formulations.
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ES2762113T3 (en) * 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Methods of providing weight loss therapy in patients with major depression
AU2011289407B2 (en) 2010-08-11 2015-06-18 Philadelphia Health & Education Corporation Novel D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
WO2012074042A1 (en) * 2010-12-03 2012-06-07 日本曹達株式会社 Hydroxyalkyl cellulose
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR101939710B1 (en) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 Hepatitis b antiviral agents
EP4104824A1 (en) 2012-06-06 2022-12-21 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
EP2874997A4 (en) 2012-07-19 2016-01-06 Univ Drexel Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
EP3158995B1 (en) 2012-08-09 2018-05-23 Dynamis Therapeutics, Inc. Meglumine for reducing high triglyceride levels
EP2941233B1 (en) 2013-01-07 2020-10-07 The Trustees of the University of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
US10166207B2 (en) 2013-06-05 2019-01-01 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2014284267B2 (en) 2013-07-02 2018-05-10 Ecoplanet Environmental Llc Volatile organic compound formulations having antimicrobial activity
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3074049B1 (en) 2013-11-26 2020-05-06 Yale University Novel cell-penetrating compositions and methods using same
EP3079692A4 (en) 2013-12-09 2017-10-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
CA2982270C (en) 2014-04-07 2023-01-10 Women & Infants Hospital Of Rhode Island Novel 7-dehydrocholesterol derivatives and methods using same
CA2968215A1 (en) 2014-08-20 2016-02-25 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
KR20160081646A (en) * 2014-12-31 2016-07-08 건일제약 주식회사 An oral composite tablet containing melatonin and sertraline
WO2016182968A1 (en) 2015-05-08 2016-11-17 Brown University Novel syringolin analogues and methods of making and using same
AU2016264364B2 (en) 2015-05-19 2022-06-23 Yale University Compositions for treating pathological calcification conditions, and methods using same
KR20180014778A (en) * 2015-06-03 2018-02-09 트리아스텍 인코포레이티드 Formulations and uses thereof
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
KR102207539B1 (en) 2015-06-30 2021-01-26 네우라드 리미티드 Novel respiratory control modulating compounds, and methods of making and using the same
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
EP3368505B1 (en) 2015-10-28 2023-02-22 Yale University Quinoline amides and methods of using same
CA3005142A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
US20190119364A1 (en) 2016-04-29 2019-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
WO2018026764A1 (en) 2016-08-01 2018-02-08 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
WO2018027024A1 (en) 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
BR112019002538A2 (en) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. use of a pharmaceutical composition comprising an allosteric modulator, use of a pharmaceutical composition comprising garboxadol or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for parenteral administration
CN109843379B (en) 2016-09-01 2022-12-30 梅比斯发现公司 Substituted ureas and methods of making and using the same
CA3040919A1 (en) 2016-11-07 2018-05-11 Arbutus Biopharma Corporation Substituted pyridinone-containing tricyclic compounds, and methods using same
EP4219486A1 (en) 2017-01-19 2023-08-02 Temple University of the Commonwealth System of Higher Education Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
US11098010B2 (en) 2017-03-21 2021-08-24 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
EP3612184A4 (en) 2017-04-17 2021-01-20 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
ES2928071T3 (en) 2017-06-16 2022-11-15 Amneal Complex Products Res Llc Gastroretentive dosage forms for sustained drug delivery
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
EP3659307A4 (en) 2017-07-28 2021-09-22 Yale University Anticancer Drugs and Methods of Making and Using Same
CA3074017A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of Colorado, A Body Corporate Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
WO2019104316A1 (en) 2017-11-27 2019-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds, compositions, and methods for treating and/or preventing periodontal disease
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
CN116270513A (en) 2018-01-09 2023-06-23 南京三迭纪医药科技有限公司 A compound oral pharmaceutical dosage form containing fixed dose of ADHD non-agonist and ADHD agonist
US11325920B2 (en) 2018-01-24 2022-05-10 The Rockefeller University Antibacterial compounds, compositions thereof, and methods using same
CN112204025B (en) 2018-05-29 2022-05-31 瑟赛治疗公司 Compounds for the treatment of pain, compositions comprising the same and methods of using the same
DK3824881T3 (en) 2018-06-18 2022-05-09 Amneal Complex Products Res Llc Composition comprising extended release pyridostigmine bromide
CN112839661A (en) 2018-10-11 2021-05-25 萨尼菲特治疗有限公司 Inositol phosphates for the treatment of ectopic calcification
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
TWI827760B (en) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
CN113365636A (en) 2019-01-30 2021-09-07 萨尼菲特治疗有限公司 Phosphoinositide compounds for increasing tissue perfusion
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
CN110151722A (en) * 2019-05-07 2019-08-23 上海新生源医药集团有限公司 A kind of stomach dissolution type clarithromycin slow-released tablet and its production technology
US11524048B2 (en) 2019-05-09 2022-12-13 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
CN110638791A (en) * 2019-10-31 2020-01-03 浙江普利药业有限公司 Topiramate sustained-release capsule and preparation method thereof
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
MX2022006014A (en) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolone for use in treating tuberous sclerosis complex.
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
IL298853A (en) 2020-06-09 2023-02-01 Inozyme Pharma Inc Soluble enpp1 or enpp3 proteins and uses thereof
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
CN112451511B (en) * 2020-12-31 2022-06-24 寿光富康制药有限公司 Metformin hydrochloride preparation and preparation method thereof
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2024023360A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip5 substituted compounds
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA722664B (en) 1971-05-18 1973-01-31 Smith Kline French Lab Lyered bolus for animal husbandry providing for immediate and sustained release of medicament
DE2460891C2 (en) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
JPS6216413A (en) * 1985-07-12 1987-01-24 Teijin Ltd Sustained release pharmaceutical composition using chitin derivative
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4894476A (en) 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US5085865A (en) 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
DE3928183A1 (en) 1989-08-25 1991-02-28 Goedecke Ag LACTAM-FREE CYCLIC AMINO ACIDS
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
IT1256393B (en) 1992-11-17 1995-12-04 Inverni Della Beffa Spa MULTI-LAYER MATERIAL FORMS FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS
IT1264696B1 (en) 1993-07-09 1996-10-04 Applied Pharma Res PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED
DK0711146T3 (en) * 1993-07-22 2000-10-16 Pfizer Osmotic device with a water-permeable coating
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
SI9520049A (en) * 1994-05-06 1997-12-31 Pfizer Controlled-release dosage forms of azithromycin
JP3962108B2 (en) * 1995-04-03 2007-08-22 中外製薬株式会社 Sucralfate-containing pharmaceutical composition
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR0134537Y1 (en) * 1995-09-30 1999-03-20 송향화 Spoon with permanent magnets
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
IT1276130B1 (en) 1995-11-14 1997-10-27 Gentili Ist Spa GLIBENCLAMIDE-METFORMIN ASSOCIATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND THEIR USE IN THE TREATMENT OF TYPE DIABETES MELLITUS
JP3220373B2 (en) 1995-11-28 2001-10-22 バイエル薬品株式会社 Long-acting nifedipine preparation
IT1282650B1 (en) 1996-02-19 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
ES2248908T7 (en) 1997-06-06 2014-11-24 Depomed, Inc. Dosage forms of drugs orally and gastric retention for continued release of highly soluble drugs
GB9711962D0 (en) * 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
US6294690B1 (en) 1997-10-07 2001-09-25 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
TW477702B (en) 1997-10-23 2002-03-01 Dev Center Biotechnology Controlled release tacrine dosage form
FR2772615B1 (en) 1997-12-23 2002-06-14 Lipha MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES
ID26082A (en) * 1998-03-19 2000-11-23 Briston Myers Squib Company DWIFASA CONTROLLED REMOVAL DELIVERY SYSTEM FOR HIGH SOLUTION PHARMACY SUBSTANCES AND ITS METHODS
KR100520589B1 (en) * 1998-04-09 2005-10-10 로쉐 디아그노스틱스 게엠베하 Carvedilol-galenics
JP3290970B2 (en) * 1998-07-22 2002-06-10 山之内製薬株式会社 Solid preparation containing poorly soluble NSAIDs
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
FR2784583B1 (en) 1998-10-16 2002-01-25 Synthelabo PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE
DE19860698A1 (en) * 1998-12-30 2000-07-06 Hexal Ag New pharmaceutical composition
KR100694667B1 (en) * 1999-12-08 2007-03-14 동아제약주식회사 Antifungal compositions containing itraconazole with both improved bioavailability and narrow intra- and inter-individual variation of its absorption
ES2270982T3 (en) * 2000-02-04 2007-04-16 Depomed, Inc. DOSAGE FORM OF NUCLEO AND CARCASA THAT IS APPROXIMATE TO A RELEASE OF THE ZERO ORDER PHARMACO.
US6461639B2 (en) 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
US6270797B1 (en) 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
BR0213079A (en) * 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Dosage form for the treatment of diabetes mellitus

Also Published As

Publication number Publication date
MXPA04007371A (en) 2004-11-26
EP1469838A1 (en) 2004-10-27
JP2005521674A (en) 2005-07-21
TWI280141B (en) 2007-05-01
EP1469838A4 (en) 2009-03-25
WO2003066028A1 (en) 2003-08-14
TW200302743A (en) 2003-08-16
KR100680574B1 (en) 2007-02-08
AU2003207755B2 (en) 2006-10-12
CA2417686C (en) 2006-06-06
AU2003207755A1 (en) 2003-09-02
NZ534312A (en) 2006-02-24
US6682759B2 (en) 2004-01-27
KR20040079980A (en) 2004-09-16
US20030147952A1 (en) 2003-08-07
IL163205A (en) 2009-07-20

Similar Documents

Publication Publication Date Title
CA2417686A1 (en) Manufacture of oral dosage forms delivering both immediate release and sustained release drugs
EP1555022B1 (en) Sustained release formulation of acetaminophen and tramadol
ES2462536T3 (en) Multi-layer orodispersible tablet
TWI242451B (en) Pharmaceutical dosage forms for controlled release producing at least a timed pulse
EP2184058B1 (en) Drug coating providing high drug loading and methods for providing the same
AU742049B2 (en) Orally disintegrable tablet forming a viscous slurry
CA2446712C (en) System for osmotic delivery of pharmaceutically active agents
CN1119993C (en) Amino-phenol acetate, pseudoephedrine, chlorpheniramine maleate and with and without dextromethorphan rotary granulating and coating
EP3175848A1 (en) Multi-layer controlled-release tablet comprising an active layer and one or more barrier layers
KR20090029710A (en) Transmucosal composition
JP2004203897A (en) Alkyl-substituted cellulose-based sustained-release oral drug dosage form
MXPA97001465A (en) Formulation of acetaminofeno, liberacion sosten
JP2013079265A (en) Buprenorphine-wafer for drug substitution therapy
CN1747723B (en) Composition comprising a mixture of active principles, and method of preparation
JP2006527184A (en) Orally dispersible multilayer tablets
CN101505735A (en) Pharmaceutical compositions for sustained release of phenyephrine
CA2543454A1 (en) Drug-containing coated microparticles for quick-disintegrating oral tablets
CA2593016A1 (en) Taste masking system for non-plasticizing drugs
CN101636153A (en) Time-specific delayed/pulsatile release dosage forms
WO2001026633A1 (en) Tablets coated with locust bean gum, guar gum or carrageenan gum
Miller et al. Advanced formulation design: improving drug therapies for the management of severe and chronic pain
JP2004217566A (en) Method for enhancing gel strength of preparation and sustained-release preparation
WO2004037226B1 (en) Pharmaceutical compositions containing venlafaxine
JPS6034910A (en) Oral snore controlling agent
Usnale et al. BILAYER TABLET

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160201